Blog
RSS FeedPosted by Michael Wonder on 10 Jul 2023
Recommendations made out of session by the PBAC March 2023 and July 2023 meetings – changes to MS-2 Step PBS listing
11 July 2023 - In an out of session consideration, the PBAC has recommended changes to the restriction criteria and eligible ...
Posted by Michael Wonder on 07 Jul 2023
PBS subsidy arrangements for insulin degludec and insulin aspart
7 July 2023 - The Department of Health and Aged Care has made amendments to the National Health (Pharmaceutical Benefits) (Pharmacist ...
Posted by Michael Wonder on 03 Jul 2023
Pharmacies get major financial boost from 1 July
3 July 2023 - On the 75th anniversary of the Chifley Labor Government’s introduction of the PBS, Australia’s strong and sustainable ...
Posted by Michael Wonder on 02 Jul 2023
Widened eligibility for oral antiviral Paxlovid, plus new medicines on PBS
2 July 2023 - From 1 July 2023, Australians with severe thrombocytopenia and diabetic kidney disease will have access to ...
Posted by Michael Wonder on 01 Jul 2023
Schedule of Pharmaceutical Benefits - 1 July 2023
1 July 2023 - The July 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Jul 2023
Changes to the National Immunisation Program effective 1 July 2023
30 June 2023 - From 1 July 2023, Vaxelis will be added to the National Immunisation Program as an alternative ...
Posted by Michael Wonder on 30 Jun 2023
Public summary documents – March 2023 PBAC meeting
30 June 2023 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2023 PBAC ...
Posted by Michael Wonder on 30 Jun 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee
30 June 2023 - More documents are now available. ...
Posted by Michael Wonder on 29 Jun 2023
Commonwealth loses appeal in clopidogrel PBS damages undertaking case: important lessons for patentees and generics alike
27 June 2023 - Commonwealth claims on the damages undertaking remain a live issue for patentees and generics to consider. ...
Posted by Michael Wonder on 28 Jun 2023
Breast cancer survivor wants $7,000 a month wonder drug to be more readily available to patients
23 June 2023 - A young Wollongong mother has spoken about her "remarkable" recovery from a breast cancer that had ...
Posted by Michael Wonder on 28 Jun 2023
2023-24 cost recovery implementation statement for listing medicines on the PBS and designated vaccines on the NIP
28 June 2023 - 2023-24 Pharmaceutical Benefits Scheme and National Immunisation Program cost recovery fees commence on 1 July 2023. ...
Posted by Michael Wonder on 27 Jun 2023
60 day drug dispensing subject of new Pharmacy Guild attack
27 June 2023 - Pharmacies have launched a major campaign against Labor’s 60 day medicine dispensing, urging the federal government ...
Posted by Michael Wonder on 24 Jun 2023
Lower medicine costs for chronic health conditions
23 June 2023 - Under the first stage of the 60 day dispensing policy, eligible Australians living with chronic health conditions ...
Posted by Michael Wonder on 23 Jun 2023
Changes to PBS eligibility criteria for Paxlovid
23 June 2023 - In an out of session consideration, the PBAC has recommended changes to the circumstances under which nirmatrelvir ...
Posted by Michael Wonder on 17 Jun 2023
Australian health insurers and pharmaceutical companies reckon with new psychedelic mental health treatments
17 June 2023 - Medicinal cannabis companies are trying to get a foothold in Australia's new psychedelics market, with therapies ...